Bilobectomy in non-small cell lung carcinoma: an analysis of indications and outcome with a review of the literature

Year 2016, Volume: 1 Issue: 1, 6 - 11, 28.12.2016

Özgür Samancılar , Tevfik İlker Akçam , Şeyda Örs Kaya Onur Akçay Kenan Can Ceylan Serpil Sevinç Şaban Ünsal

Abstract

Background: The gold standard of treatment for non-small cell lung cancer (NSCLC) is anatomic pulmonary resection. Wider resection methods may be preferred due to the size or anatomic location of the tumor. One method of choice is bilobectomy due of the anatomy of the right lung.

Materials and Methods: This study retrospectively analyzed 93 patients who were diagnosed with NSCLC and had bilobectomy, complete resection, and mediastinal lymph node dissection at our center between January 2005 and April 2013.

Results: Forty-seven patients underwent superior bilobectomy (sBL), and 46 patients underwent inferior bilobectomy (iBL). Bilobectomy was performed due to fissure invasion in 51 (58.1%) patients, internal or external bronchial tumor invasion in 31 (33.3%) patients, external bronchial lymph node invasion in six (6.4%) patients, and vascular invasion in two (2.2%) patients. The bronchial invasion-based indications were significantly higher in the iBL group compared to the fissure invasion-based indications in the sBL group (P < 0.001).

Conclusions: Bilobectomy leads to a substantial amount of parenchymal loss in the right lung, but it is a procedure that should be performed under the necessary conditions. It is obvious that performing bilobectomy under proper indications would result in good outcomes for lung cancer patients.

Keywords

Bilobectomy, lung cancer

References

• Massard G, Dabbagh A, Dumont P, Kessler R, Roeslin N, Wihlm JM, et al. Are bilobectomies acceptable procedures? Ann Thorac Surg 1995; 60: 640-5.
• Icard P, Heyndrickx M, Galateau-Salle F, Rosat P, Lerochais JP, Gervais R, et al. Does bilobectomy offer satisfactory long-term survival outcome for non-small cell lung cancer? Ann Thorac Surg 2013; 9: 1726-33.
• Churchill ED. The surgical treatment of carcinoma of the lung. J Thorac Surg 1933; 2: 254-66.
• Galetta D, Solli P, Borri A, Petrella F, Gasparri R, Brambilla D, et al. Bilobectomy for lung cancer: analysis of indications, postoperative results, and long-term outcomes. Ann Thorac Surg 2012; 93: 251-7.
• Keller SM, Kaiser LR, Martini N. Bilobectomy for bronchogenic carcinoma. Ann Thorac Surg 1988; 45: 62-5.
• Deneuville M, Regnard JF, Coggia M, Rojas-Miranda A, Dartevelle P, Levasseur P. The place for bilobectomy in bronchogenic carcinoma. Eur J Cardiothorac Surg 1992; 6: 446-51.
• Carbognani P, Tincani G, Solli P, Galimberti A, Cattelani L, Bobbio A, et al. The bilobectomies for lung cancer. J Cardiovasc Surg 2001; 42: 421-4.
• Kim AW, Faber LP, Warren WH, Shah ND, Basu S, Liptay MJ. Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg 2010; 139: 606-11.
• Gomez MT, Jimenez MF, Aranda JL, Rodriguez M, Novoa NM, Varela G. The risk of bilobectomy compared with lobectomy: a retrospective analysis of a series of matched cases and controls. Eur J Cardiothorac Surg 2014; 16: 72-75.
• Cerfolio RJ. The incidence, etiology, and prevention of postresectional bronchopleural fistula. Semin Thorac Cardiovasc Surg 2001; 13: 3-7.
• Vester SR, Faber LP, Kittle CF, Warren WH, Jensik JR. Bronchopleural fistula after stapled closure of bronchus. Ann Thorac Surg 1991; 52: 1253-7.
• 2011 ESTS Database Annual Report 2011. Available at: http://www.ests.org/ documents/ PDF/ Database silver book 2011.pdf. Accessed June 10, 2012.